Lung Cancer Trial, Recruiting NCT06926179 Sponsor: Peking University Cancer Hospital & Institute Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT06926179
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with non-small cell lung cancer (a specific type of lung cancer), confirmed by a laboratory test on a tissue sample, regardless of whether certain gene changes (EGFR or ALK) are present in your cancer
  • Your cancer was staged as early to locally advanced (stages IA through IIIC) before starting any pre-surgery treatment, based on a standard staging system
  • You have already received at least one round of pre-surgery immunotherapy treatment (which may or may not have included chemotherapy)
  • Doctors who specialize in surgery determined that your tumor could be surgically removed, or potentially surgically removed, before treatment began

Who may not be able to join:

  • Your cancer has already spread to distant parts of the body (confirm with trial site)
  • You have a history of a previous lung cancer or another cancer that has spread to other parts of the body
  • You are already taking part in another clinical trial that involves pre-surgery treatment
  • Important information about your medical history or treatment is missing from your records

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0086-10-88196569

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Peking University Cancer Hospital & Institute
Registry
ClinicalTrials.gov
Start date
1 December 2024
Est. completion
31 March 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Technical Dissection Difficulty (TDD) Rate; Disease-Free Survival (DFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov